SciClone Pharmaceuticals Inc (SCLN)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:SciClone Pharmaceuticals Inc (SCLN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014376
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
SciClone Pharmaceuticals Inc (SciClone) develops and commercializes products for the treatment of cancer, cardiovascular disorders and infectious diseases. The company’s lead product, Zadaxin (thymalfasin), an immunostimulatory agent approved for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), sepsis, certain cancers, and as an immune system enhancer. SciClone also markets other pharmaceutical products in China including DC Bead, a product for the embolization of malignant hypervascularized tumors. It also has several drug candidates in various clinical development states intended for the treatment of cancer and cardiovascular diseases. The company has presence in Beijing and Shanghai in China; Hong Kong and Vietnam. SciClone is headquartered in Foster City, California, the US.

SciClone Pharmaceuticals Inc (SCLN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
SciClone Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
SciClone Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
SciClone Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
SciClone Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
SciClone Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
SciClone Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Soligenix Enters Into Co-Marketing Agreement With SciClone Pharma For SGX942 12
Sanofi-Aventis Expands Co-Promotion Agreement with NovaMed Pharma 13
Licensing Agreements 14
SciClone Pharma Enters into Licensing Agreement with Soligenix 14
SciClone Pharma Enters into Licensing Agreement with Ability Pharma 15
Phosplatin Therapeutics Enters into Licensing Agreement with SciClone Pharma 16
Theravance Biopharma Enters into Co-Development Agreement with SciClone Pharma 17
Medicines Company Enters into Licensing Agreement with SciClone 18
SciClone Pharma Enters Into Licensing Agreement With Taiwan Liposome For ProFlow 20
SciClone Pharma And Zensun (Shanghai) Science & Technology Enter Into Licensing Agreement For Neucardin 21
Equity Offering 23
SciClone Pharma Files Registration Statement For Public Offering Of Securities For US$100 Million 23
Acquisition 25
GL Capital Led Consortium Acquires SciClone Pharma for up to USD605 Million 25
SciClone Pharma Acquires NovaMed Pharma 27
SciClone Pharmaceuticals Inc – Key Competitors 29
SciClone Pharmaceuticals Inc – Key Employees 30
SciClone Pharmaceuticals Inc – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Financial Announcements 32
Aug 09, 2017: SciClone Reports Second Quarter 2017 Financial Results 32
May 10, 2017: SciClone Reports First Quarter 2017 Financial Results 34
Mar 06, 2017: SciClone Reports 2016 Financial Results And 2017 Outlook 36
Nov 09, 2016: SciClone Reports Third Quarter 2016 Financial Results 38
Aug 09, 2016: SciClone Reports Second Quarter 2016 Financial Results 40
May 10, 2016: SciClone Reports First Quarter 2016 Financial Results 42
Mar 10, 2016: SciClone Reports 2015 Financial Results 43
Jan 11, 2016: SciClone Announces Preliminary 2015 Revenue 45
Other Significant Developments 46
Jul 19, 2016: SciClone Provides Update On Strategic Review Process 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
SciClone Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
SciClone Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
SciClone Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
SciClone Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
SciClone Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
SciClone Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Soligenix Enters Into Co-Marketing Agreement With SciClone Pharma For SGX942 12
Sanofi-Aventis Expands Co-Promotion Agreement with NovaMed Pharma 13
SciClone Pharma Enters into Licensing Agreement with Soligenix 14
SciClone Pharma Enters into Licensing Agreement with Ability Pharma 15
Phosplatin Therapeutics Enters into Licensing Agreement with SciClone Pharma 16
Theravance Biopharma Enters into Co-Development Agreement with SciClone Pharma 17
Medicines Company Enters into Licensing Agreement with SciClone 18
SciClone Pharma Enters Into Licensing Agreement With Taiwan Liposome For ProFlow 20
SciClone Pharma And Zensun (Shanghai) Science & Technology Enter Into Licensing Agreement For Neucardin 21
SciClone Pharma Files Registration Statement For Public Offering Of Securities For US$100 Million 23
GL Capital Led Consortium Acquires SciClone Pharma for up to USD605 Million 25
SciClone Pharma Acquires NovaMed Pharma 27
SciClone Pharmaceuticals Inc, Key Competitors 29
SciClone Pharmaceuticals Inc, Key Employees 30
SciClone Pharmaceuticals Inc, Subsidiaries 31

★海外企業調査レポート[SciClone Pharmaceuticals Inc (SCLN)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Dimension Data Holdings Plc:企業の戦略的SWOT分析
    Dimension Data Holdings Plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Ridley Corporation Ltd:企業の戦略・SWOT・財務情報
    Ridley Corporation Ltd - Strategy, SWOT and Corporate Finance Report Summary Ridley Corporation Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Bank of the West:企業の戦略・SWOT・財務情報
    Bank of the West - Strategy, SWOT and Corporate Finance Report Summary Bank of the West - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • GOBARTO S.A.:企業の戦略・SWOT・財務情報
    GOBARTO S.A. - Strategy, SWOT and Corporate Finance Report Summary GOBARTO S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Incyte Corp (INCY)-製薬・医療分野:企業M&A・提携分析
    Summary Incyte Corp (Incyte) is a biopharmaceutical company that discovers, develops, and commercializes proprietary cancer therapeutics. The company’s lead product, Jakafi (ruxolitinib) is marketed in the US for the treatment of patients with high-risk myelofibrosis as well as patients with polycyt …
  • OnKure Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary OnKure Inc (OnKure) is a drug developer that discovers and develops epigenetic therapies for the treatment of cancer. The company offers production of specific histone deacetylases inhibitors. Its lead product candidate ONK102 significantly reduces the growth rate of tumors in hematological …
  • General Dynamics Ordnance and Tactical Systems, Inc.:企業の戦略・SWOT・財務情報
    General Dynamics Ordnance and Tactical Systems, Inc. - Strategy, SWOT and Corporate Finance Report Summary General Dynamics Ordnance and Tactical Systems, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's st …
  • ULURU Inc (ULUR)-医療機器分野:企業M&A・提携分析
    Summary ULURU Inc (ULURU) is a developer and commercializer of wound care and muco-adhesive film products. The company’s products include Altrazeal and OraDisc. Its Altrazeal is a transforming powder dressing with Nanoflex technology for the management of exuding wounds. ULURU’s OraDisc is a polymer …
  • PhaseBio Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary PhaseBio Pharmaceuticals Inc (PhaseBio) is a clinical-stage biopharmaceutical company that develops biotherapeutics for the treatment of orphan diseases and cardiopulmonary indications. The company offers ELP biopolymer technology, which includes PE0139 and PB1023 pipeline products. PhaseBio …
  • Mentor Graphics Corporation:企業のM&A・事業提携・投資動向
    Mentor Graphics Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Mentor Graphics Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • Prescient Therapeutics Ltd (PTX):製薬・医療:M&Aディール及び事業提携情報
    Summary Prescient Therapeutics Ltd (Prescient Therapeutics), formerly Virax Holdings Ltd, is a clinical stage oncology company that develops novel drugs for the treatment of solid and hematological cancers. The company’s lead drug candidate includes PTX-200, a potent small molecule inhibitor of the …
  • Idaho Power Co:企業の発電所・SWOT分析2018
    Idaho Power Co - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (exe …
  • Escorts Ltd:企業の戦略・SWOT・財務情報
    Escorts Ltd - Strategy, SWOT and Corporate Finance Report Summary Escorts Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • ABT Molecular Imaging Inc:医療機器:M&Aディール及び事業提携情報
    Summary ABT Molecular Imaging Inc (ABT) is a medical imaging company engaged in the development of biomarker generator systems and related accessories. Its technology platform BG-75, a biomarker generator produces unit doses of molecular imaging drugs for positron emission tomography (PET) at the po …
  • Bonheur ASA (BON):企業の財務・戦略的SWOT分析
    Summary Bonheur ASA (Bonheur) is an oil and gas investment service provider that offers investment services for various energy sectors. The company invests in renewable energy, cruise, shipping and offshore wind, offshore drilling, and other investments. It operates shipping vessels for transport an …
  • Wacoal Holdings Corp (3591):企業の財務・戦略的SWOT分析
    Wacoal Holdings Corp (3591) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • CeQur SA:医療機器:M&Aディール及び事業提携情報
    Summary CeQur SA (CeQur) is a medical device company that develops and commercializes insulin delivery systems. The company offers product PAQ, a wearable insulin delivery device, which delivers both basal and bolus doses. Its PAQ product consist two components such as insulin reservoir and messenge …
  • Par Pacific Holdings, Inc. (PARR):企業の財務・戦略的SWOT分析
    Par Pacific Holdings, Inc. (PARR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Guided Therapeutics Inc (GTHP):医療機器:M&Aディール及び事業提携情報
    Summary Guided Therapeutics Inc (GTI), formerly SpectRx Inc is a biotechnology company that offers platform technology for the early detection of disease that leads to cancer. The company provides products for the non-invasive cervical cancer detection markets. Its products include luviva, a non-inv …
  • NIKE Inc:企業の戦略・SWOT・財務情報
    NIKE Inc - Strategy, SWOT and Corporate Finance Report Summary NIKE Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆